Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Unicycive Therapeutics In...

    NASDAQ: UNCY · Real-Time Price · USD
    4.08
    -0.62 (-13.19%)
    At close: Aug 18, 2025, 3:59 PM
    4.10
    0.37%
    After-hours: Aug 18, 2025, 07:36 PM EDT
    -13.19%
    Bid 3.96
    Market Cap 52.16M
    Revenue (ttm) n/a
    Net Income (ttm) -15.2M
    EPS (ttm) -0.56
    PE Ratio (ttm) -7.29
    Forward PE 0.26
    Analyst Buy
    Ask 4.24
    Volume 2,075,743
    Avg. Volume (20D) 754,650
    Open 4.79
    Previous Close 4.70
    Day's Range 3.86 - 4.79
    52-Week Range 2.83 - 11.00
    Beta 1.87

    About UNCY

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol UNCY
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for UNCY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Unicycive Therapeutics Inc. is scheduled to release its earnings on Nov 12, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    -29.85%
    Unicycive Therapeutics shares are trading lower af... Unlock content with Pro Subscription
    2 months ago
    -8.89%
    Unicycive Therapeutics shares are trading lower after the company announced a 1-for-10 reverse stock split effective June 20, 2025.
    news image

    1 day ago · businesswire.com

    UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

    LOS ANGELES--(BUSINESS WIRE)---- $UNCY--UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

    news image

    1 day ago · businesswire.com

    SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics

    NEW YORK--(BUSINESS WIRE)---- $UNCY #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or t...

    news image

    3 weeks ago · seekingalpha.com

    Unicycive Therapeutics: Manageable CMC Speed-Bump--Pill-Burden Edge Intact, Buying

    Initiating coverage on Unicycive Therapeutics, Inc. with a Buy rating and $6 price target, as the recent FDA CRL is manufacturing-related and resolvable. OLC's ultra-low pill burden and strong patient...

    news image

    1 month ago · businesswire.com

    UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation With the Schall Law Firm

    LOS ANGELES--(BUSINESS WIRE)---- $UNCY--UNCY Investors Have Opportunity to Join Unicycive Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.

    Add to Watchlist